journal
https://read.qxmd.com/read/38758815/gz17-6-02-kills-pdx-isolates-of-uveal-melanoma
#1
JOURNAL ARTICLE
Laurence Booth, Jane L Roberts, Ivan Spasojevic, Kaitlyn C Baker, Andrew Poklepovic, Cameron West, John M Kirkwood, Paul Dent
GZ17-6.02 has undergone phase I evaluation in patients with solid tumors (NCT03775525). The RP2D is 375 mg PO BID, with an uveal melanoma patient exhibiting a 15% reduction in tumor mass for 5 months at this dose. Studies in this manuscript have defined the biology of GZ17-6.02 in PDX isolates of uveal melanoma cells. GZ17-6.02 killed uveal melanoma cells through multiple convergent signals including enhanced ATM-AMPK-mTORC1 activity, inactivation of YAP/TAZ and inactivation of eIF2α. GZ17-6.02 significantly enhanced the expression of BAP1, predictive to reduce metastasis, and reduced the levels of ERBB family RTKs, predicted to reduce growth...
May 17, 2024: Oncotarget
https://read.qxmd.com/read/38753413/the-anticancer-potential-of-the-clk-kinases-inhibitors-1c8-and-gps167-revealed-by-their-impact-on-the-epithelial-mesenchymal-transition-and-the-antiviral-immune-response
#2
JOURNAL ARTICLE
Lulzim Shkreta, Johanne Toutant, Aurélie Delannoy, David Durantel, Anna Salvetti, Sophie Ehresmann, Martin Sauvageau, Julien A Delbrouck, Alice Gravel-Trudeau, Christian Comeau, Caroline Huard, Jasmin Coulombe-Huntington, Mike Tyers, David Grierson, Pierre-Luc Boudreault, Benoit Chabot
The diheteroarylamide-based compound 1C8 and the aminothiazole carboxamide-related compound GPS167 inhibit the CLK kinases, and affect the proliferation of a broad range of cancer cell lines. A chemogenomic screen previously performed with GPS167 revealed that the depletion of components associated with mitotic spindle assembly altered sensitivity to GPS167. Here, a similar screen performed with 1C8 also established the impact of components involved in mitotic spindle assembly. Accordingly, transcriptome analyses of cells treated with 1C8 and GPS167 indicated that the expression and RNA splicing of transcripts encoding mitotic spindle assembly components were affected...
May 16, 2024: Oncotarget
https://read.qxmd.com/read/38753318/retraction-knockdown-of-trim65-inhibits-lung-cancer-cell-proliferation-migration-and-invasion-a-therapeutic-target-in-human-lung-cancer
#3
JOURNAL ARTICLE
Xiao-Lin Wang, Wei-Ping Shi, Hong-Can Shi, Shi-Chun Lu, Kang Wang, Chao Sun, Jian-Sheng He, Wei-Guo Jin, Xiao-Xia Lv, Hui Zou, Yu-Sheng Shu
No abstract text is available yet for this article.
May 16, 2024: Oncotarget
https://read.qxmd.com/read/38742684/cyclin-d1-expression-in-penile-cancer
#4
JOURNAL ARTICLE
Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim Khayat, José Ribamar Rodrigues Calixto, Marcos Adriano Garcia Campos, Rita da Graça Carvalhal Frazão Correa, Antonio Machado Alencar Júnior, Antônio Augusto Lima Teixeira-Júnior, Gyl Eanes Barros Silva
The main goal of the present study was to analyze the expression profile of cyclin D1 in patients with PC, and to determine possible correlations with clinical and histopathological features. A survey was conducted with 100 patients diagnosed with PC, who were treated at two reference hospitals in São Luís, Maranhão, Brazil, between 2013 and 2017. A review of clinical, epidemiological, and histopathological data was performed, Human Papillomavírus (HPV) DNA was detected using polymerase chain reaction (PCR) and cyclin D1 expression analysis was performed using immunohistochemical techniques...
May 14, 2024: Oncotarget
https://read.qxmd.com/read/38742682/retraction-chronically-high-level-of-tgfb1a-induction-causes-both-hepatocellular-carcinoma-and-cholangiocarcinoma-via-a-dominant-erk-pathway-in-zebrafish
#5
Chuan Yan, Qiqi Yang, Han-Ming Shen, Jan M Spitsbergen, Zhiyuan Gong
No abstract text is available yet for this article.
May 14, 2024: Oncotarget
https://read.qxmd.com/read/38712741/deep-learning-based-whole-body-psma-pet-ct-attenuation-correction-utilizing-pix-2-pix-gan
#6
JOURNAL ARTICLE
Kevin C Ma, Esther Mena, Liza Lindenberg, Nathan S Lay, Phillip Eclarinal, Deborah E Citrin, Peter A Pinto, Bradford J Wood, William L Dahut, James L Gulley, Ravi A Madan, Peter L Choyke, Ismail Baris Turkbey, Stephanie A Harmon
PURPOSE: Sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation dosage. We propose an artificial intelligence (AI) tool to produce attenuation-corrected PET (AC-PET) images from non-attenuation-corrected PET (NAC-PET) images to reduce need for low-dose CT scans. METHODS: A deep learning algorithm based on 2D Pix-2-Pix generative adversarial network (GAN) architecture was developed from paired AC-PET and NAC-PET images...
May 7, 2024: Oncotarget
https://read.qxmd.com/read/38712739/correction-gap-junction-mediated-transfer-of-mir-145-5p-from-microvascular-endothelial-cells-to-colon-cancer-cells-inhibits-angiogenesis
#7
Dominique Thuringer, Gaetan Jego, Kevin Berthenet, Arlette Hammann, Eric Solary, Carmen Garrido
No abstract text is available yet for this article.
May 7, 2024: Oncotarget
https://read.qxmd.com/read/38709242/transfected-sars-cov-2-spike-dna-for-mammalian-cell-expression-inhibits-p53-activation-of-p21-waf1-trail-death-receptor-dr5-and-mdm2-proteins-in-cancer-cells-and-increases-cancer-cell-viability-after-chemotherapy-exposure
#8
JOURNAL ARTICLE
Shengliang Zhang, Wafik S El-Deiry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 infection has led to worsened outcomes for patients with cancer. SARS-CoV-2 spike protein mediates host cell infection and cell-cell fusion that causes stabilization of tumor suppressor p53 protein. In-silico analysis previously suggested that SARS-CoV-2 spike interacts with p53 directly but this putative interaction has not been demonstrated in cells. We examined the interaction between SARS-CoV-2 spike, p53 and MDM2 (E3 ligase, which mediates p53 degradation) in cancer cells using an immunoprecipitation assay...
May 3, 2024: Oncotarget
https://read.qxmd.com/read/38588464/exploring-the-role-of-ghrh-antagonist-mia-602-in-overcoming-doxorubicin-resistance-in-acute-myeloid-leukemia
#9
JOURNAL ARTICLE
Simonetta I Gaumond, Rama Abdin, Joel Costoya, Andrew V Schally, Joaquin J Jimenez
Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorubicin-resistant AML cell lines, KG-1A, U-937, and K-562...
April 8, 2024: Oncotarget
https://read.qxmd.com/read/38502947/durvalumab-and-tremelimumab-before-surgery-in-patients-with-hormone-receptor-positive-her2-negative-stage-ii-iii-breast-cancer
#10
JOURNAL ARTICLE
Haven R Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E Adrada, Padmanee Sharma, Elizabeth A Mittendorf, Jennifer K Litton
A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease...
March 19, 2024: Oncotarget
https://read.qxmd.com/read/38497774/from-osimertinib-to-preemptive-combinations
#11
JOURNAL ARTICLE
Mikhail V Blagosklonny
Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual PFS in 15-20% of patients compared to first-generation TKIs. Since detecting a single resistant cell before treatment is usually impossible, osimertinib must be used in all patients as a first-line treatment, raising median PFS overall but harming some. The simplest remedy is a preemptive combination (PC) of osimertinib and gefitinib...
March 15, 2024: Oncotarget
https://read.qxmd.com/read/38484153/abt199-venetoclax-synergism-with-thiotepa-enhances-the-cytotoxicity-of-fludarabine-cladribine-and-busulfan-in-aml-cells
#12
JOURNAL ARTICLE
Benigno C Valdez, Bin Yuan, David Murray, Jeremy L Ramdial, Uday Popat, Yago Nieto, Borje S Andersson
ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. Its efficacy in hematopoietic stem cell transplantation (HSCT), when combined with other chemotherapeutic drugs, has not been thoroughly investigated. The present study demonstrates the synergistic cytotoxicity of ABT199/venetoclax with the DNA alkylator thiotepa (Thio) in AML cells. Cleavage of Caspase 3, PARP1 and HSP90, as well as increased Annexin V positivity, suggest potent activation of apoptosis by this two-drug combination; increased levels of γ-H2AX, P-CHK1 (S317), P-CHK2 (S19) and P-SMC1 (S957) indicate an enhanced DNA damage response...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484152/analytical-validation-of-next-personal%C3%A2-an-ultra-sensitive-personalized-circulating-tumor-dna-assay
#13
JOURNAL ARTICLE
Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C P Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C Bruce, Laurie J Goodman, Yi Chen, Dan Norton, Richard O Chen, John M Lyle
We describe the analytical validation of NeXT Personal® , an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to ~1,800 somatic variants specific to the patient's tumor. A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484151/g-quadruplex-landscape-and-its-regulation-revealed-by-a-new-antibody-capture-method
#14
JOURNAL ARTICLE
Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama Ghosh, Akanksha Mudgal, Divyesh Patel, Thenmalarchelvi Rathinavelan, Umashankar Singh
Our understanding of DNA G-quadruplexes (G4s) from in vitro studies has been complemented by genome-wide G4 landscapes from cultured cells. Conventionally, the formation of G4s is accepted to depend on G-repeats such that they form tetrads. However, genome-wide G4s characterized through high-throughput sequencing suggest that these structures form at a large number of regions with no such canonical G4-forming signatures. Many G4-binding proteins have been described with no evidence for any protein that binds to and stabilizes G4s...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484150/correction-sigma-1-and-sigma-2-receptor-ligands-induce-apoptosis-and-autophagy-but-have-opposite-effect-on-cell-proliferation-in-uveal-melanoma
#15
Lucia Longhitano, Carlo Castruccio Castracani, Daniele Tibullo, Roberto Avola, Maria Viola, Giuliano Russo, Orazio Prezzavento, Agostino Marrazzo, Emanuele Amata, Michele Reibaldi, Antonio Longo, Andrea Russo, Nunziatina Laura Parrinello, Giovanni Li Volti
No abstract text is available yet for this article.
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38441437/gz17-6-02-interacts-with-proteasome-inhibitors-to-kill-multiple-myeloma-cells
#16
JOURNAL ARTICLE
Laurence Booth, Jane L Roberts, Cameron West, Paul Dent
GZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375 mg PO BID. GZ17-6.02 was more efficacious as a single agent at killing multiple myeloma cells than had previously been observed in solid tumor cell types. GZ17-6.02 interacted with proteasome inhibitors in a greater than additive fashion to kill myeloma cells and alone it killed inhibitor-resistant cells to a similar extent...
March 5, 2024: Oncotarget
https://read.qxmd.com/read/38386842/correction-yk-4-279-effectively-antagonizes-ews-fli1-induced-leukemia-in-a-transgenic-mouse-model
#17
Tsion Zewdu Minas, Jenny Han, Tahereh Javaheri, Sung-Hyeok Hong, Michaela Schlederer, Yasemin Saygideğer-Kont, Haydar Çelik, Kristina M Mueller, Idil Temel, Metin Özdemirli, Heinrich Kovar, Hayriye Verda Erkizan, Jeffrey Toretsky, Lukas Kenner, Richard Moriggl, Aykut Üren
No abstract text is available yet for this article.
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386812/correction-combination-treatment-with-rucaparib-rubraca-and-mdm2-inhibitors-nutlin-3-and-rg7388-has-synergistic-and-dose-reduction-potential-in-ovarian-cancer
#18
Maryam Zanjirband, Nicola Curtin, Richard J Edmondson, John Lunec
No abstract text is available yet for this article.
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386807/prevalence-and-spectrum-of-germline-brca1-and-brca2-in-a-cohort-of-ovarian-cancer-patients-from-the-salento-peninsula-southern-italy-a-matter-of-preventive-health
#19
JOURNAL ARTICLE
Elisabetta De Matteis, Maria Rosaria Tumolo, Paolo Tarantino, Mariangela Ciccarese, Tiziana Grassi, Francesco Bagordo, Maria Rita De Giorgio, Emanuele Rizzo, Graziana Ronzino
OBJECTIVES: The aim of this exploratory, descriptive study was to characterize the deleterious BRCA1 and BRCA2 variants evaluated by genetic testing in a group of Ovarian cancer patients living in the Salento peninsula (Southern Italy). METHODS: From June 2014 to July 2023, patients with histologically confirmed high-grade serous carcinoma, fallopian tube, or primary peritoneal cancer who were referred to Lecce Familial Cancer Clinic were considered. BRCA-mutation genetic testing was performed on these patients...
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386805/sacituzumab-govitecan-plus-platinum-based-chemotherapy-mediates-significant-antitumor-effects-in-triple-negative-breast-urinary-bladder-and-small-cell-lung-carcinomas
#20
JOURNAL ARTICLE
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan, Chien-Hsing Chang, David M Goldenberg
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer...
February 22, 2024: Oncotarget
journal
journal
43072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.